98
Registered trials
37
Recruiting
50
Completed trials
32
Sponsors
22
Countries
Phase III:
53
Phase II/III:
1
Phase II:
20
Phase I/II:
3
Phase III/IV:
2
Phase IV:
17
Phase I (Other):
2
Oversight events:
3 serious breaches
20 temporary halts
3 urgent safety measures
3 corrective measures
across 8 trials
View oversight register →
Indications tested
Non-small cell lung cancer
9
Crohn's disease
6
Hepatocellular carcinoma
4
Non-small cell lung cancer metastatic
3
Triple negative breast cancer
3
Small cell lung cancer extensive stage
2
Cholangiocarcinoma
2
Rheumatoid arthritis
2
Colitis ulcerative
2
Inflammatory bowel disease
2
Non-small cell lung cancer stage I
1
Non-small cell lung cancer stage IIIB
1
Sponsors using this IMP
AstraZeneca AB
61
Assistance Publique Hopitaux De Paris
3
Amgen Inc.
2
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
2
UZ Leuven
2
Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
2
Aalborg University Hospital
1
Aarhus University Hospital
1
Alimentiv Inc.
1
Amsterdam UMC Stichting
1
Belgian IBD Research and Development
1
Biocompatibles UK Limited
1
All trials
98 total-
The OASE study Pending
-
STARS (Secukinumab in TAkayasu ARteritiS) Recruiting
Showing 1–24 of 98 trials